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Intracardiac lipid accumulation can cause heart failure. A study in Journal of Clinical Investigation (Son et al.,
2010) found that cardiac-specific PPARg overexpression caused heart failure with intracardiac triglyceride
accumulation. Overexpressing PPARg on a PPARa/ background improved cardiac function, suggesting
that specific lipid metabolites and lipid packaging determine cardiac lipotoxicity.Over the last 40 years, there has been
a leap forward in the ability to prevent
heart disease through diet, physical
activity, and aggressive medical manage-
ment of hypertension and blood lipids
(van Dam and Willett, 2009). Unfortu-
nately, in the United States, this has
been a missed opportunity, as there is
a continued high rate of heart disease,
largely attributable to physical inactivity,
excessive energy intake, and resultant
obesity. Obesity triggers hypertension,
hyperlipidemia, glucose intolerance, and
diabetes, which cause atherosclerosis,
cardiac hypertrophy, ischemic heart
disease, and ultimately heart failure (Lavie
et al., 2009) (see Figure 1). It has been
proposed that independent of these es-
tablished risk factors, intracardiac accu-
mulation of lipids could exert toxic effects
on the myocardium that would directly
cause cardiac dysfunction, cell death,
and the development of heart failure
(Unger, 2002; Schaffer, 2003). Investiga-
tion into this hypothesis has placed
growing emphasis on understanding the
role of specific fatty acyl metabolites and
intracellular packaging of lipid stores as
potential mediators of the toxic effects of
lipids in the heart.
In a recent issue of Journal of Clinical
Investigation, Son et al. addressed this
hypothesis by altering the capacity for
lipid import and oxidation and analyzing
the resulting cardiac phenotype (Son
et al., 2010). They observed that PPARg
overexpression in the heart caused di-
lated cardiomyopathy and poor survival
that was associated with intracardiac
triglyceride accumulation. Crossing this
cardiac-specific PPARg-overexpressingmouse with a PPARa/ mouse
increased cardiac fatty acid oxidation
and lipid droplet size, which corre-
sponded with improved cardiac contrac-
tile function and survival despite no differ-
ence in total myocardial triglyceride
stores and an elevation in myocardial
free fatty acid levels. The authors empha-
sized the potential pathogenic signifi-
cance of this pattern of intracellular lipid
storage, arguing that larger droplets
have reduced total surface area and are
likely to reflect more inert lipid storage
while smaller ones may trigger harmful
molecular pathways. While this cross did
not result in lower diacylglycerol or ce-
ramide levels, these mice had increased
long-chain fatty acyl-CoAs and
decreased acylcarnitines and various
markers of cell stress. These findings
add further support for the concept that
neither cardiac storage of triglycerides
nor oxidation of fatty acids is inherently
detrimental to the heart and suggest that
specific fatty acyl derivatives may be
responsible for the toxic effect of lipid
accumulation. Of particular interest is
the relationship between accumulation
of long-chain fatty acyl carnitines and
poor cardiac function and survival, as
these compounds are associated with
effects on sarcolemmal ion channels
that cause cardiac arrhythmias (Corr and
Yamada, 1995), which are the main cause
of death in heart failure patients.
The changes in the activity in PPARa
and PPARg induced by deletion and
overexpression are extreme and thus are
not comparable to the relatively subtle
changes caused by diet or pharmacolog-
ical agents in humans. Nevertheless,Cell Metabolism 12,important information is gained from this
work, particularly the observation that
large changes in fatty acid uptake, oxida-
tion, and storage do not predict changes
in cardiac function or development of
pathology, but rather activation of patho-
logical processes is dependent on the
manner in which triglyceride is stored
and the changes in specific lipid metabo-
lites. Unger and others proposed that the
toxic effects of specific lipids contribute
to the development and progression of
heart failure through mechanisms that
are independent of traditional well-estab-
lished mechanisms depicted in Figure 1
(Unger, 2002; Schaffer, 2003). It is impor-
tant to note that lipids synergize with toxic
pathways involving glucose metabolism
to injure the heart via glucolipotoxicity,
and in obesity, high levels of insulin and
leptin can stimulate prohypertrophic and
pathologic signaling processes, which all
together provide a ‘‘perfect storm’’ for
the development of heart failure (Taegt-
meyer and Stanley, 2010). Interestingly,
PPARa/ mice overexpressing cardiac
PPARg had a 30% reduction in blood
glucose. While insulin and leptin levels
were not reported in these mice, it seems
quite possible that the beneficial effects
observed could be partially due to sup-
pression of glucolipotoxicity and detri-
mental metabolic hormone signaling.
How do we apply these findings to the
clinical problem of heart failure associ-
ated with obesity and type II diabetes?
It is now well established that the risk
for new-onset heart failure increases
progressively with severity of obesity;
however, once heart failure has been
diagnosed, there is an ‘‘obesity paradox,’’December 1, 2010 ª2010 Elsevier Inc. 555
Figure 1. Potential Role of Cardiac Lipid Accumulation in the Pathophysiology of Heart
Failure
Heart failure is initiated by established risk factors (maroon boxes, solid arrows) and possible effects
of intracardiac lipid accumulation (dashed gray box and arrows). Chronic hypertension, ischemia,
diabetes/glucose intolerance, old age, and environmental toxins like tobacco smoke trigger molecular
and physiological mechanisms leading to myocardial hypertrophy, fibrosis, changes in neurohormonal
regulation, tachycardia, inflammation, etc., which ultimately lead to the classic systolic and diastolic
dysfunction and arrhythmias found with heart failure. Less clear is the role for myocardial lipid accumula-
tion in these processes. Studies in cells and genetically altered mice established the possibility that
various lipid moieties could trigger pathological mechanisms.
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Previewswith better survival in obese heart failure
patients compared to those with normal
body mass (Lavie et al., 2009). Presum-
ably this is due to differences in the
etiology of heart failure between normal-
weight and obese heart failure patients,
with a less malignant form of heart failure
with obesity. It is also possible that heart
failure in some obese patients is exacer-556 Cell Metabolism 12, December 1, 2010 ªbated by accumulation of specific lipids
and unidentified pathological mecha-
nisms. It would be extremely useful to
have a clinical marker for toxic lipid moie-
ties detectable by diagnostic imaging or
in cardiac biopsies. It is also important
to investigate therapeutic interventions,
such as low-carbohydrate/high-fat diets,
which are frequently used for weight loss2010 Elsevier Inc.and maintenance and affect myocardial
lipid metabolism and expression of
PPAR-regulated genes (Chess and Stan-
ley, 2008). Drugs that inhibit myocardial
fatty acid oxidation, such as trimetazidine
and perhexiline, show promise in small
trials in heart failure patients, though the
mechanism of action is not clear and the
specific effects in obese heart failure
patients have not been investigated
(Lopaschuk et al., 2010). The findings of
Son et al. provide important insight into
the mechanisms by which lipid metabo-
lism and storage can become cardiotoxic,
and they illustrate the importance of
moving forward to evaluate these
processes in animal models of human
obesity and obese heart disease patients.REFERENCES
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